FN2 Earnings Intelligence
Edwards Lifesciences Corporation balance sheet (quarterly)
Edwards Lifesciences Corporation (EW) Balance Sheet (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 est. | 9/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - | - | - |
| - Cash | $3,676.4 | $3,140.6 | $3,272.8 | $2,685.6 | $2,445.5 | - | - |
| + Debt | - | - | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - | - | - |
| Revenue | $1,354.4 | $1,412.7 | $1,532.2 | $1,553.1 | $1,648.6 | $1,700.2 | $1,676.8 |
| % Growth | - | - | - | - | - | 11.0% | 8.0% |
| Gross Profit | $1,091.5 | $1,111.1 | $1,187.8 | $1,207.9 | $1,286 | - | - |
| % Margin | 80.6% | 78.7% | 77.5% | 77.8% | 78.0% | - | - |
| EBITDA | - | $431.4 | - | - | $518.5 | - | - |
| % Margin | - | 30.5% | - | - | 31.5% | - | - |
| Net Income | $3,070.8 | $358 | $333.2 | $291.1 | $380.7 | - | - |
| % Margin | 226.7% | 25.3% | 21.7% | 18.7% | 23.1% | - | - |
| Diluted EPS | $5.13 | $0.61 | $0.56 | $0.50 | $0.66 | $0.74 | $0.74 |
| % Growth | - | - | - | - | - | 32.7% | 47.9% |
| Operating Cash Flow | - | $280.4 | - | - | $43.8 | - | - |
| CapEx | - | $56 | - | - | $64.9 | - | - |
| Free Cash Flow | - | $224.4 | - | - | -$21.1 | - | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 est. | 9/30/2026 est. |
|---|---|---|---|---|---|---|---|
| Revenue | $1,354.4 | $1,412.7 | $1,532.2 | $1,553.1 | $1,648.6 | $1,700.2 | $1,676.8 |
| Gross Profit | $1,091.5 | $1,111.1 | $1,187.8 | $1,207.9 | $1,286 | - | - |
| EBITDA | - | $431.4 | - | - | $518.5 | - | - |
| Net Income | $3,070.8 | $358 | $333.2 | $291.1 | $380.7 | - | - |
| Diluted EPS | $5.13 | $0.61 | $0.56 | $0.50 | $0.66 | $0.74 | $0.74 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $3,676.4 | $3,140.6 | $3,272.8 | $2,685.6 | $2,445.5 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $597.5 | $597.8 | $598 | $598.2 | $598.5 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | $280.4 | - | - | $43.8 |
| Capital Expenditure | - | $56 | - | - | $64.9 |
| Free Cash Flow | - | $224.4 | - | - | -$21.1 |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 9/30/2024 | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | 80.6% | 78.7% | 77.5% | 77.8% | 78.0% |
| EBITDA Margin | - | 30.5% | - | - | 31.5% |
| Net Margin | 226.7% | 25.3% | 21.7% | 18.7% | 23.1% |
| FCF Margin | - | 15.9% | - | - | -1.3% |
| Diluted EPS Growth | - | - | - | - | - |